阿加曲班联合丁苯酞软胶囊对穿支动脉脑梗死患者NIHSS评分与生活质量的影响

陈佳; 陈向宇; 骆嵩

doi:10.16766/j.cnki.issn.1674-4152.002541

阿加曲班联合丁苯酞软胶囊对穿支动脉脑梗死患者NIHSS评分与生活质量的影响

doi: 10.16766/j.cnki.issn.1674-4152.002541

陈佳^1, ,,
陈向宇¹,
骆嵩²

1.
铜陵市人民医院神经内科，安徽铜陵 244000
2.
蚌埠医学院第一附属医院神经内科安徽蚌埠 233004

基金项目:

安徽省高校自然科学研究重点项目 KJ2019A0364

详细信息

通讯作者:
陈佳, E-mail: 799726653@qq.com

中图分类号: R743.3
计量
- 文章访问数: 258
- HTML全文浏览量: 102
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-25
- 网络出版日期: 2022-09-23

Effects of argatroban combined with butylphthalide soft capsule on NIHSS score and quality of life in patients with perforating cerebral infarction

1.
Department of Neurology, Tongling People's Hospital, Tongling, Anhui 244000, China

摘要

摘要: 目的分析阿加曲班联合丁苯酞软胶囊治疗穿支动脉脑梗死的临床效果。方法选择2017年6月—2020年6月间铜陵市人民医院神经内科诊治的76例穿支动脉脑梗死患者为研究对象，采用随机数字表法分为研究组(39例)与对照组(37例)。对照组在常规治疗基础上联合应用硫酸氢氯吡格雷片，研究组采用阿加曲班联合丁苯酞软胶囊。比较2组患者美国国立卫生研究院卒中量表(National Institute of Health stroke scale，NIHSS)评分、Barthel指数(Barthel index，BI)、进展性运动障碍(progressive muscular dystrophy，PMD)发生率、神经功能恢复(mRS评分)情况，采用世界卫生组织生存质量测量量表(World Health Organization Quality of Life-100，WHOQOL-100)评价生活质量。结果研究组与对照组12周时NIHSS评分分别为(4.1±1.7)分、(5.6±1.5)分，研究组显著低于对照组(P＜0.05)；BI评分分别为(76.9±16.3)分、(68.3±13.7)分，研究组显著高于对照组(P＜0.05)；2组患者mRS评分分别为(2.6±0.6)分、(2.9±0.8)分，差异无统计学意义(P＞0.05)。12周时生活质量评价结果显示，研究组生理健康、社会关系、独立能力评分显著高于对照组(均P＜0.05)。结论阿加曲班联合丁苯酞软胶囊对穿支动脉脑梗死患者具有较好的治疗效果，有较高的应用价值。
- 阿加曲班 /
- 丁苯酞软胶囊 /
- 穿支动脉脑梗死 /
- 美国国立卫生研究院卒中量表评分 /
- 生活质量
Abstract: Objective To determine the clinical effect of argatroban combined with butylphthalide soft capsules in the treatment of perforating cerebral infarction. Methods Seventy-six patients with perforating cerebral infarction were enrolled and randomly divided into the study group (n=39) and control group (n=37). The patients in the control group were given clopidogrel bisulphate tablets on the basis of conventional therapy, and those in the study group were given argatroban and butylphthalide soft capsules. The National Institute of Health stroke scale (NIHSS) score, Barthel index (BI), incidence of progressive muscular dystrophy (PMD) and neurological recovery (mRS score) were compared. The World Health Organization Quality of Life-100 was used to evaluate the quality of life. Results At the 12th week, the NIHSS scores of the study group and control group were (4.1±1.7) points and (5.6±1.5) points, respectively. The study group had a significantly lower score (P < 0.05). The BI scores of the study group and control group were (76.9±16.3) points and (68.3±13.7) points, respectively. The study group had a significantly higher score (P < 0.05). The mRS scores of the study group and control group were (2.6±0.6) points and (2.9±0.8) points, respectively, with no statistical difference (P > 0.05). The results of the quality of life evaluation showed that the scores of physiological health, social relations and independent ability of the study group were significantly higher than those of the control group (all P < 0.05). Conclusion Argatroban combined with butylphthalide soft capsules has a good therapeutic effect and high application value on patients with perforating cerebral infarction.
- Argatroban /
- Butylphthalide soft capsule /
- Perforator cerebral infarction /
- NHISS score /
- Quality of life

HTML全文

表 1 2组PAD型脑梗死患者一般资料比较

Table 1. Comparison of general data of patients with PAD cerebral infarction between two groups

组别	例数	年龄(x±s，岁)	性别[例(%)]		入院时NHISS评分(x±s，分)	基础疾病[例(%)]			发病至入院间隔时间(x±s，h)
组别	例数	年龄(x±s，岁)	男性	女性	入院时NHISS评分(x±s，分)	高血压	糖尿病	冠心病	发病至入院间隔时间(x±s，h)
研究组	39	61.5±9.3	23(59.0)	16(41.0)	10.7±3.6	20(51.3)	15(38.5)	3(7.7)	13.2±3.4
对照组	37	60.2±8.7	25(67.6)	12(32.4)	10.2±3.4	18(48.6)	12(32.4)	5(13.5)	14.3±4.6
统计量		0.628^a	0.603^b		0.622^a	0.053^b	0.301^b	0.205^b	1.317^a
P值		0.532	0.438		0.536	0.818	0.583	0.651	0.192
注：^a为t值，^b为χ²值。

下载: 导出CSV

表 2 2组PAD型脑梗死患者NHISS评分比较(x±s，分)

Table 2. Comparison of NHISS score between two groups of patients with PAD cerebral infarction (x±s, points)

组别	例数	入院时	3周	12周
研究组	39	10.7±3.6	7.1±2.0^a	4.1±1.7^ab
对照组	37	10.2±3.4	7.9±1.8^a	5.6±1.5^ab
t值		0.622	1.830	4.070
P值		0.536	0.071	＜0.001
注：与入院时比较，^aP＜0.05;与3周时比较，^bP＜0.05。

下载: 导出CSV

表 3 2组PAD型脑梗死患者BI评分与mRS评分比较(x±s，分)

Table 3. BI score and mRS score in two groups of PAD cerebral infarction patients Comparison(x±s, points)

组别	例数	BI评分		mRS评分
组别	例数	7 d	12周	7 d	12周
研究组	39	55.1±19.4	76.9±16.3	3.4±0.9	2.6±0.6
对照组	37	57.3±18.2	68.3±13.7	3.2±0.7	2.9±0.8
t值		0.509	2.483	1.077	1.856
P值		0.612	0.015	0.285	0.068

下载: 导出CSV

表 4 2组PAD型脑梗死患者WHOQOL-100评价结果(x±s，分)

Table 4. Evaluation of WHOQOL-100 in two groups of patients with pad type cerebral infarction result(x±s, points)

组别	例数	心理状态		生理健康
组别	例数	7 d	12周	7 d	12周
研究组	39	7.2±1.5	11.9±2.0	7.4±2.0	14.5±2.7
对照组	37	7.5±1.1	11.3±1.4	7.1±1.7	12.1±2.4
t值		0.990	1.507	0.703	4.088
P值		0.326	0.136	0.484	＜0.001

组别	例数	独立能力		社会关系
组别	例数	7 d	12周	7 d	12周
研究组	39	8.2±0.9	14.2±3.0	8.9±1.4	14.0±2.9
对照组	37	8.4±1.5	13.0±2.1	8.4±1.9	12.7±2.0
t值		0.709	2.010	1.311	2.263
P值		0.481	0.048	0.194	0.027

组别	例数	周围环境		个人信仰
组别	例数	7 d	12周	7 d	12周
研究组	39	9.4±2.3	13.8±3.0	9.1±1.6	14.3±1.6
对照组	37	8.9±1.6	13.1±2.7	8.6±1.3	13.8±2.0
t值		1.095	1.067	1.490	1.207
P值		0.277	0.289	0.140	0.231

下载: 导出CSV

参考文献(15)

[1]	谷欣荣, 张晓中. 脑梗死患者血清同型半胱氨酸水平与患者病情严重程度的关系[J]. 安徽医学, 2017, 38(12): 1597-1599. doi: 10.3969/j.issn.1000-0399.2017.12.029 GU X R, ZHANG X Z. Erum homocysteine level and condition of patients with cerebral infarction Relationship of severity[J]. Anhui Medical Journal, 2017, 38(12): 1597-1599. doi: 10.3969/j.issn.1000-0399.2017.12.029
[2]	王冬欣, 李易明, 张志涛, 等. 血浆同型半胱氨酸水平与中国缺血性卒中亚型关系的研究[J]. 河北医药, 2018, 40(14): 2193-2142. doi: 10.3969/j.issn.1002-7386.2018.14.028 WANG D X, LI Y M, ZHANG Z T, et al. Correlation between Chinese ischemic stroke subtype and the levels of plasma homocysteine[J]. Hebei Medical Journal, 2018, 40(14): 2193-2142. doi: 10.3969/j.issn.1002-7386.2018.14.028
[3]	潘能毅, 武志全, 林树楷, 等. 血液生化指标主成分回归模型用于脑梗死患者CISS分型[J]. 贵阳医学院学报, 2020, 45(1): 237-242. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYB202002022.htm AN N Y, WU Z Q, LIN S K, et al. Principal Component Regression Model of Blood Biochemical Index for CISS Classification of Cerebral Infarction Patients[J]. Journal of Guiyang Medical College, 2020, 45(1): 237-242. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYB202002022.htm
[4]	TAKEUCHI M, MIYASHITA K, NAKAGAWARA J, et al. Analysis of factors associated with progression and long-term outcomes of penetrating artery territory infarction: A retrospective study[J]. J Stroke Cerebrovasc Dis, 2016, 25(8): 1952-1959. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.007
[5]	田婷, 关智媛, 石正洪, 等. 复发性缺血性脑卒中的危险因素、严重程度及短期预后分析[J]. 中国康复理论与实践, 2016, 22(2): 172-177. doi: 10.3969/j.issn.1006-9771.2016.02.011 TIAN T, GUAN Z Y, SHI Z H, et al. Risk Factors, Severity and Short-term Outcome of Recurrent Ischemic Stroke[J]. Chinese Journal of Rehabilitation Theory and Practice, 2016, 22(2): 172-177. doi: 10.3969/j.issn.1006-9771.2016.02.011
[6]	SUN S Y, WANG Y Q, WANG Y G, et al. Lipid and hyperglycemia factors in first-ever penetrating artery infarction, a comparison between different subtypes[J]. Brain Behav, 2017, 7(6): e00694. DOI: 10.1002/brb3.694.
[7]	FRANCESCA P, PUNITHA A, MARCUS M, et al. Short-versus long-term dual anti-platelet therapy (DAPT) in Secondary prevention for ischaemic stroke-a network meta-analysis[J]. Eur Heart J Qual Care Clin Outcomes, 2019, 5(4): 298-309. doi: 10.1093/ehjqcco/qcz024
[8]	LIU Y, LI F, SUN H W, et al. Combined prognostic significance of D-dimer level and platelet count in acute ischemic stroke[J]. Thrombosis Research, 2020, 194: 142-149. doi: 10.1016/j.thromres.2020.05.021
[9]	SCALAMBRINO E, PADOVAN L, CHANTARANGKUL V, et al. Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study[J]. Int J Lab Hematol, 2020, 42(2 suppl): e128-e131.
[10]	吉智, 范秀博. 注射用红花黄色素联合阿加曲班治疗急性脑梗死的临床研究[J]. 现代药物与临床, 2016, 31(2): 158-162. https://www.cnki.com.cn/Article/CJFDTOTAL-GWZW201602007.htm JI Z, FAN X B. Clinical study of Safflower Yellow for injection combined with argatroban in treatment of acute cerebral infarction[J]. Drugs & Clinic, 2016, 31(2): 158-162. https://www.cnki.com.cn/Article/CJFDTOTAL-GWZW201602007.htm
[11]	苏观利, 黎永仙, 王华, 等. 阿加曲班、氯吡格雷与丁苯酞联合治疗进展性脑梗死的疗效及安全性研究[J]. 临床急诊杂志, 2017, 18(10): 775-778. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLC201710015.htm SU G L, LI Y X, WANG H, et al. Efficacy and safety of combined use of argatroban and clopidogrel and butylphthalide in the treatment of progressive cerebral infarction[J]. Journal of Clinical Emergency, 2017, 18(10): 775-778. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLC201710015.htm
[12]	WANG X L, WANG L N, HUANG Z J, et al. Synthesis and biological evaluation of nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide as potential antiplatelet agents[J]. Bioorg Med Chem Lett, 2013, 23: 1985-1988. doi: 10.1016/j.bmcl.2013.02.035
[13]	张伟平, 屈洪党, 许力. 丁苯酞注射液对脑梗死患者血清细胞凋亡因子水平的影响[J]. 中华全科医学, 2019, 17(7): 1087-1089, 1190. doi: 10.16766/j.cnki.issn.1674-4152.000869 ZHANG W P, QU H D, XU L. Effect of butylphthalide injection on the serum level of apoptosis-related factors in patients with cerebral infarction[J]. Chinese Journal of General Practice, 2019, 17(7): 1087-1089, 1190. doi: 10.16766/j.cnki.issn.1674-4152.000869
[14]	陆冰, 刘洲, 林智君, 等. 丁苯酞对血管性痴呆患者脑循环动力学及血管内皮功能的影响[J]. 浙江医学, 2018, 40(13): 1443-1446, 1450. doi: 10.12056/j.issn.1006-2785.2018.40.13.2018-173 LU B, LI Z, LIN Z J, et al. Effects of butylphthalide on cerebral circulation dynamics and vascular endothelial function in patients with vascular dementia[J]. Zhejiang Medical Journal, 2018, 40(13): 1443-1446, 1450. doi: 10.12056/j.issn.1006-2785.2018.40.13.2018-173
[15]	顾媛媛, 冯来会. 丁苯酞软胶囊联合高压氧对老年急性脑梗死患者转化生长因子β1、尿酸水平及生活质量的影响[J]. 中国老年学杂志, 2019, 39(10): 2322-2326. doi: 10.3969/j.issn.1005-9202.2019.10.007 GU Y Y, FENG L H. Effect of butylphthalide soft capsule combined with hyperbaric oxygen on transforming growth factor-β1, uric acid level and quality of life in elderly patients with acute cerebral infarction[J]. Chinese Journal of Gerontology, 2019, 39(10): 2322-2326. doi: 10.3969/j.issn.1005-9202.2019.10.007